Cancer Targeted Technology LLC has disclosed conjugates comprising a glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) targeting ligand covalently linked to a therapeutic or diagnostic agent through a linker reported to be useful for the treatment of prostate cancer.
Cholangiocarcinoma includes several biliary malignant tumors that have poor prognosis. Post-translational modifications in proteins lead to abnormal protein dynamics and disturbances that may cause pathology.
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by frequent local recurrences and metastases. To identify compounds that could be repurposed to treat MCC, National Institutes of Health (NIH) researchers performed a high-throughput cell viability screen of 3,908 small molecules.
Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while mitigating the toxicity limitations of current monoclonal antibody therapies.
Histone deacetylase 3 (HDAC3) is involved in transcriptional regulation, phosphorylation and the inhibition of tumor suppressor genes. Its upregulation in several types of tumors, such as colorectal, prostate, breast and ovarian cancers, among others, makes it a potential therapeutic target in cancer.
Insilico Medicine founder and CEO Alex Zhavoronkov told BioWorld that he tries to spend as much time as possible in China, because that's where the artificial intelligence (AI) drug development company conducts synthesis and tests for early stage discovery. “And nowadays, not a day goes by without somebody launching an AI drug discovery company,” he said, noting that Chinese AI company Deepseek could be a huge disrupter.
RSS
